Off-Label Drug Uses — This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Wolters Kluwer Health. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form, so the reader can easily identify the scope of information available. A summary of the data—including background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments regarding “Off-Label Drug Uses” to hospitalpharmacy@wolterskluwer.com.
Get full access to this article
View all access options for this article.
References
1.
BorghiL., MeschiT., AmatoF.Nifedipine and methylprednisolone in facilitating ureteral stone passage: a randomized, double-blind, placebo-controlled study. J Urol.1994; 152(4): 1095–1098.
2.
PorpigliaF., DestefanisP., FioriC., FontanaD.Effectiveness of nifedipine and deflazacort in the management of ureteral stones. Urology.2000; 56(4): 579–582.
3.
PorpigliaF., GhignoneG., FioriC., FontanaD., ScarpaR.M.Nifedipine versus tamsulosin for the management of lower ureteral stones. J Urol.2004; 172(2): 568–571.
4.
DellabellaM., MilaneseG., MuzzonigroG.Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi. J Urol.2005; 174(1): 167–172.
5.
SaitaA., BonaccorsiA., MarcheseF., CondorelliS.V., MottaM.Our experience with nifedipine and prednisolone as expulsive therapy for ureteral stones. Urol Int.2004; 72(Suppl 1): 43–45.
6.
AnagnostouT., TolleyD.Management of ureteric stones. Eur Urol.2004; 45(6): 714–721.
7.
ChandhokeP.S.Economics of urolithiasis: cost-effectiveness of therapies. Curr Opin Urol.2001; 11(4): 391–393.
8.
KakizakiH., AmedaK., KobayashiS., TanakaH., ShibataT., KoyanangiT.Urodynamic effects of alpha1-blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder. Int J Urol.2003; 10(11): 576–581.
9.
LotanY., GettmanM.T., RoehrbornC.G., CadedduJ.A., PearleM.S.Management of ureteral calculi: a cost comparison and decision making analysis. J Urol.2002; 167(4): 1621–1629.
10.
ReitzA., HaferkampA., KyburzT., KnappP.A., WeferB., SchurchB.The effect of tamsulosin on the resting tone and the contractile behaviour of the female urethra: a functional urodynamic study in healthy women. Eur Urol.2004; 46(2): 235–240.
11.
SandhuC., AnsonK.M., PatelU.Urinary tract stones—Part I: role of radiological imaging in diagnosis and treatment planning. Clin Radiol.2003; 58(6): 415–421.
12.
SandhuC., AnsonK.M., PatelU.Urinary tract stones—Part II: current status of treatment. Clin Radiol.2003; 58(6): 422–433.
13.
TiseliusH.G., AckermannD., AlkenP., BuckC., ConortP., GallucciM.; Working Party on Lithiasis, European Association of Urology. Guidelines on urolithiasis. Eur Urol.2001; 40(4): 362–371.
